Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,240 | 2 | 78.8% |
| Unspecified | $1,000 | 1 | 9.6% |
| Travel and Lodging | $729.40 | 2 | 7.0% |
| Food and Beverage | $403.67 | 15 | 3.9% |
| Gift | $90.00 | 1 | 0.9% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $6,000 | 2 | $0 (2023) |
| EISAI INC. | $3,306 | 2 | $0 (2022) |
| PFIZER INC. | $729.40 | 2 | $0 (2017) |
| Allergan Inc. | $222.19 | 2 | $0 (2017) |
| Sunovion Pharmaceuticals Inc. | $151.93 | 11 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $53.39 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $5,000 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($5,000) |
| 2022 | $4,240 | 2 | EISAI INC. ($3,240) |
| 2021 | $70.35 | 6 | Sunovion Pharmaceuticals Inc. ($70.35) |
| 2020 | $23.99 | 1 | Novartis Pharmaceuticals Corporation ($23.99) |
| 2019 | $36.48 | 2 | Sunovion Pharmaceuticals Inc. ($36.48) |
| 2018 | $29.40 | 1 | Novartis Pharmaceuticals Corporation ($29.40) |
| 2017 | $1,063 | 8 | PFIZER INC. ($729.40) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/24/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| 08/02/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS | ||||||
| 02/03/2022 | EISAI INC. | — | Consulting Fee | Cash or cash equivalent | $3,240.00 | General |
| 10/07/2021 | Sunovion Pharmaceuticals Inc. | KYNMOBI (Drug) | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: CNS | ||||||
| 06/25/2021 | Sunovion Pharmaceuticals Inc. | KYNMOBI (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: CNS | ||||||
| 05/13/2021 | Sunovion Pharmaceuticals Inc. | KYNMOBI (Drug) | Food and Beverage | In-kind items and services | $11.14 | General |
| Category: CNS | ||||||
| 03/19/2021 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $19.51 | General |
| Category: CNS | ||||||
| 02/25/2021 | Sunovion Pharmaceuticals Inc. | KYNMOBI (Drug) | Food and Beverage | In-kind items and services | $6.00 | General |
| Category: CNS | ||||||
| 01/26/2021 | Sunovion Pharmaceuticals Inc. | KYNMOBI (Drug) | Food and Beverage | In-kind items and services | $3.00 | General |
| Category: CNS | ||||||
| 02/21/2020 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: NEUROSCIENCE | ||||||
| 03/19/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: CNS | ||||||
| 02/26/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: CNS | ||||||
| 10/04/2018 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | Cash or cash equivalent | $29.40 | General |
| 12/07/2017 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: CNS | ||||||
| 11/29/2017 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $10.27 | General |
| Category: CNS | ||||||
| 11/28/2017 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $16.91 | General |
| Category: CNS | ||||||
| 08/03/2017 | Allergan Inc. | NATRELLE (Device) | Gift | In-kind items and services | $90.00 | General |
| Category: PLASTICS | ||||||
| 06/20/2017 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $132.19 | General |
| 05/24/2017 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $539.40 | General |
| 05/24/2017 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $190.00 | General |
| 03/30/2017 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $66.16 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS | Takeda Pharmaceuticals U.S.A., Inc. | $1,000 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 16 | 29 | $15,225 | $3,465 |
| 2022 | 1 | 15 | 28 | $13,896 | $3,254 |
| 2021 | 1 | 14 | 28 | $13,230 | $3,424 |
| 2020 | 2 | 31 | 40 | $16,235 | $4,259 |
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 29 | $15,225 | $3,465 | 22.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 28 | $13,896 | $3,254 | 23.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 14 | 28 | $13,230 | $3,424 | 25.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 16 | 25 | $11,225 | $3,147 | 28.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 15 | 15 | $5,010 | $1,113 | 22.2% |
About Stuart Lipton, M.D./PH.D
Stuart Lipton, M.D./PH.D is a Neurology healthcare provider based in La Jolla, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1578596292.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Stuart Lipton, M.D./PH.D has received a total of $10,463 in payments from pharmaceutical and medical device companies, with $5,000 received in 2023. These payments were reported across 21 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($8,240).
As a Medicare-enrolled provider, Lipton has provided services to 76 Medicare beneficiaries, totaling 125 services with total Medicare billing of $14,402. Data is available for 4 years (2020–2023), covering 5 distinct procedure/service records.
Practice Information
- Specialty Neurology
- Location La Jolla, CA
- Active Since 07/08/2006
- Last Updated 02/17/2017
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1578596292
Products in Payments
- APTIOM (Drug) $101.09
- NATRELLE (Device) $90.00
- KYNMOBI (Drug) $50.84
- MAYZENT (Drug) $23.99
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in La Jolla
Charles Smith, M.d, M.D
Neurology — Payments: $590,505
Dr. Jody Corey-Bloom, Md, Phd, MD, PHD
Neurology — Payments: $452,305
Dr. Jay Rosenberg, M.d, M.D
Neurology — Payments: $216,627
Dr. Christy Jackson, M.d, M.D
Neurology — Payments: $213,127
Dr. Emily Engel, M.d, M.D
Neurology — Payments: $151,871
Dr. Dee Silver, Md, MD
Neurology — Payments: $103,830